Toripalimab (PDCD1/PD1/CD279) - Research Grade Biosimilar
Product Specifications
Background
Toripalimab is humanized monoclonal antibody targeted at programmed death receptor 1 (PD-1), used to treat patients with unresectable or metastatic melanoma who have failed previous systemic system therapy, and is intended for treatment Breast cancer, lymphoma, malignant melanoma, urogenital cancer and other types of solid tumors.
Immunogen
Humanized / PDCD1/PD1/CD279 [Homo sapiens]
Clonality
Recombinant Monoclonal
Conjugation
Unconjugated
Type
Primary Antibodies, Biosimilars
Source
CHO cells
Field of Research
Cancer, Immunology
Purification
>95%
Concentration
Batch dependent
Buffer
PBS buffer pH7.5
Modification
None
Shipping Conditions
Blue Ice
Storage Conditions
Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8 ˚ C for 1-2 weeks. Store at -20 ˚ C for 12 months. Store at -80 ˚ C for long term storage.
Fragment
IgG4-kappa
NCBI Organism
Homo sapiens
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
GF-080-3 10 µg
Platelet derived Growth Factor (PDGF-AA) human (Recombinant)
Sign In for Pricing
View Details 
MBS1277583-01 0.01 mg Plasmid + 0.2 mL Glycerol-Stock
LIG3 cDNA Clone
Sign In for Pricing
View Details